Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Katie Kommando who wrote (38579)	3/22/2000 10:26:00 AM
From: Katie Kommando	Read Replies (1) \| Respond to of 150070

WASP . . . exciting news for WASP longs: Wednesday March 22, 8:27 am Eastern Time Company Press Release Wasatch Pharmaceutical Announces Implementation of Internet Marketing Plan MIDVALE, Utah--(BUSINESS WIRE)--March 22, 2000--Wasatch Pharmaceutical, Inc. (OTC BB: WASP - news), a leader in the research, development and distribution of dermatological treatments for skin disorders, including acne and psoriasis, today announced the implementation of its Internet Marketing Plan, to be completed within the next 90 days. ``The goal of our Marketing Plan is to facilitate the online marketing, and subsequent fulfillment, of our acne, seborrhea, folliculitis and skin rejuvenation product lines. To that end, we are capitalizing on the purchasing possibilities afforded consumers connected to the Internet,' commented Wasatch Chief Executive Officer, Gary V. Heesch.`` The Company has begun installation and networking of their production, development, and medical research servers, which were delivered on March 13, 2000. These servers will form the technical foundation for the Internet Marketing Plan. Wasatch has also developed preliminary packaging designs for its products. Once the design phase is completed, the Company will begin production of inventory to support fulfillment. Concurrently, online marketing software is being developed, and preliminary negotiations with an Internet distribution and fulfillment company are underway. Wasatch Pharmaceutical, Inc. is a leading research and development entity in the field of dermatology. The Company targets its products and treatments to a wide variety of specific dermatological disease areas, including cystic acne, psoriasis, eczema, and seborrhea. Any statements released by Wasatch Pharmaceutical, Inc. that are not strictly historical are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the company's business prospects and performance. These include economic, competitive, governmental, technological and other factors discussed in the company's filings with the Securities and Exchange Commission. Contact: National Financial Network Rick McCaffrey, 781/444-6100 ext. 14 Investor Relations or Wasatch Pharmaceutical, Inc. Gary V. Heesch, CEO 801/272-1709